Sedation Regimens for TAVR Recovery
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn whether the type of sedation medication used during a transcatheter aortic valve replacement (TAVR) affects how people recover after the procedure. The main question this study aims to answer is whether different sedation regimens (propofol, dexmedetomidine, or midazolam with fentanyl) lead to differences in quality of recovery on the first day after the procedure.
Researchers will compare three commonly used sedation medications (propofol, dexmedetomidine, or midazolam with fentanyl) to determine whether they lead to differences in recovery following a TAVR.
Participants will:
* Be enrolled before their scheduled TAVR procedure
* Be randomly assigned to receive one of the three sedation medications during their procedure
* Complete short surveys on postoperative days 1 and 7 about pain levels, how they feel during their recovery, and how satisfied they were with their anesthesia experience
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo TAVR procedure with one of three sedation regimens (propofol, dexmedetomidine, or midazolam with fentanyl)
Immediate Postoperative Monitoring
Participants are monitored in the PACU for recovery and pain management
Follow-up
Participants complete surveys on postoperative days 1 and 7 to assess quality of recovery and satisfaction with anesthesia
Extended Follow-up
Participants are monitored for 30-day readmission rates and other postoperative outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Dexmedetomidine
- Fentanyl
- Midazolam
- Propofol
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Participants will receive propofol for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Participants will receive a combination of midazolam and fentanyl for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Participants will receive dexmedetomidine for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Find a Clinic Near You
Who Is Running the Clinical Trial?
David Lyubashevsky
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.